1. Avet-Loiseau H. Ultra high-risk myeloma. Am. Soc. Hematol. Educ. Program. . 2010; :489–493. 2. Palumbo A & Anderson K. Multiple myeloma. N. Engl. J. Med. . 2011; 17(364):1046–1060. 3. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk strati ica-
tion in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Blood . 2011; 117(18):4696–700.
4. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations
t(4;14) and del(17p13) with the International Staging System classi ication allows strati ica- tion of myeloma patients undergoing autologous stem cell transplantation. Haematologica . 2010; 95(7):1150–7.
5. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, & Shaughnessy J J. Cyclin D dysregula-
tion: an early and unifying pathogenic event in multiple myeloma. Blood . 2005; 106(1):296– 303.
6. Zhan F, Huang Y, Colla S, et al. The molecular classi ication of multiple myeloma. Blood . 2006; 108(6):2020–2028.
7. Broyl A, Hose D, Lokhorst H, et al. Gene expression pro iling for molecular classi ication of
multiple myeloma in newly diagnosed patients. Blood . 2010; 116(14):2543–53.
8. Chng WJ, Kuehl WM, Bergsagel PL, & Fonseca R. Translocation t(4;14) retains prognostic sig-
ni icance even in the setting of high-risk molecular signature. Leukemia . 2008; 22(2):459–61.
9. Shaughnessy J J D, Zhan F, Burington BE, et al. A validated gene expression model of high-risk
multiple myeloma is de ined by deregulated expression of genes mapping to chromosome 1.
Blood . 2007; 109(6):2276–2284.
10. Shaughnessy J J D, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing iden-
ti ies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood . 2011; 118:3512–3524.
11. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression pro iling and correlation with out-
come in clinical trials of the proteasome inhibitor bortezomib. Blood . 2007; 109(8):3177– 3188.
12. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on
gene expression pro iles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Franco- phone du Myelome. J Clin Oncol . 2008; 26(29):4798–4805.
13. Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples
identi ies genes and an expression signature relevant to pathogenesis and outcome. Clin Can-
cer Res . 2010; 16(6):1856–1864.
14. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor
and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica . 2011; 96(1):87–95.
2
based on Mayo Strati ication of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc . 2007; 82(3):323–41.
16. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 Randomized Phase
III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). Blood . 2010; 116(21):40–40.
17. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple mye-
loma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol . 2008; 140(6):625–634.
18. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves
complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood . 2008; 112(8):3115–3121.
19. Morgan GJ, Davies FE, Gregory WM, et al. Thalidomide Maintenance Signi icantly Improves
Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results. Blood . 2010; 116(21):623–623.
20. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide Combinations Improve Response Rates;
Results from the MRC IX Study. Blood . 2007; 110(11):3593–3593.
21. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in re-
lapsed or refractory myeloma. Br Journal Haematol . 2004; 127(2):165–172.
22. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for
relapsed multiple myeloma. N Engl J Med . 2005; 352(24):2487–2498.
23. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, re-
fractory myeloma. N Engl J Med . 2003; 348(26):2609–2617.
24. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for com-
putational biology and bioinformatics. Genome Biol . 2004; 5(10):R80.
25. Johnson WE, Li C, & Rabinovic A. Adjusting batch effects in microarray expression data using
empirical Bayes methods. Biostatistics . 2007; 8(1):118–27.
26. Therneau & Lumley T. survival: Survival analysis, including penalised likelihood. R package version 2.36-2 . 2010; .
27. Bair E, Hastie T, Paul D, & Tibshirani R. Prediction by Supervised Principal Components. J Amer Statistical Assoc . 2006; 101(473):119–137.
28. Benjamini Y & Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
Approach to Multiple Testing. J Roy Stat Soc B Met . 1995; 57(1):289–300.
29. Arulampalam V, Kolosenko I, Hjortsberg L, Bjorklund AC, Grander D, & Tamm KP. Activation of
STAT1 is required for interferon-alpha-mediated cell death. Exp Cell Res . 2011; 317(1):9–19.
30. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multi-
ple myeloma is associated with increased expression and activating mutations of ibroblast growth factor receptor 3. Nat Genet . 1997; 16(3):260–4.
31. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces signi icant downregulation of
survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol . 2007; 138(6):783– 91.